

Contents

- ◇ New Formulary submissions
- ◇ New and Updated APC Guidelines
- ◇ Links to our APC webinar and podcast
- ◇ Changes we have made to our formulary
- ◇ Feature of the month
~ Inclisiran

New submissions:

Melatonin for Huntington's Disease	AMBER 2	<ul style="list-style-type: none"> Specialist initiation for the treatment of sleep disorders associated with Huntington's Disease. To be discontinued once the sleep pattern settles. It is not appropriate to use alternatives such as benzodiazepines or Z medicines in Huntington's Disease due to effects on cognition and falls risks.
A.S Saliva Orthana®	GREEN	<ul style="list-style-type: none"> pH neutral and a mucin-derived saliva substitute. Available as a spray and refill for all ACBS dry mouth conditions. Self care and purchasing over the counter should be promoted where appropriate. Due to the porcine derivative, this product is unsuitable for vegetarians and people from certain religious groups. <p style="text-align: center;">Current supply problems</p>
Doxazosin for PTSD	AMBER 2	<ul style="list-style-type: none"> Off-label use for nightmares associated with post-traumatic stress disorder. Primary care prescription should only be requested after efficacy and tolerability has been demonstrated.

News from the APC - updated/new documents:

- ⇒ [Testosterone Shared Care Protocol](#)
- ⇒ [Gynaecomastia in Adults Guideline](#)
- ⇒ [Phosphate Binders Shared Care Protocol](#)
- ⇒ [Position Statement on Liothyronine \(oral\) for Hypothyroidism](#)
- ⇒ [Frequency of Blood Glucose Testing Guideline \(New\)](#)

Antimicrobial Guidelines

- [Cellulitis](#)
- [Dermatophyte infection of the skin](#)
- [Head lice](#)
- [Mould infections of the nail](#)
- [Osteomyelitis](#)
- [Epididymitis +/- orchitis](#)
- [Prostatitis](#)

Coming soon:

- Restless legs treatment algorithm
- Alternatives to using an Unlicensed "Special"
- COPD exacerbation rescue medication
- Children and Young People (CYP) Asthma Guidance 5-17 years (New)
- Adult Asthma Treatment Summary
- Guidance on MART (New)

APC webinars A pre-recorded APC update is available to view on our [YouTube channel](#)

Our brand new Podcast

Prescribing and Interface Learning Sessions (PILS). This is a podcast brought to you by Nottingham and Nottinghamshire ICB, created to deliver the latest APC updates in a quick and easy to listen format. We hope you will find it useful. Please give us your feedback by commenting below each podcast or emailing the [Interface Team](#).

[APC Podcast](#)

Horizon scanning, formulary amendments and traffic light changes

GREY

Insuman® Rapid, Basal and Comb insulin for injection: products discontinued by the manufacturer - no new patient initiations, existing stocks can be used until stocks are exhausted, or the patient is reviewed.
Clarithromycin XL: No particular benefit from once a day administration compared to twice a day.

RED

Paliperidone depot (Byannli®) and (Trevicta®): an option for specialist prescribing for carefully selected stable patients .

AMBER 2

Uro-trainer® Polihexanide PHMB catheter irrigation solution: restricted use for patients on the catheter patency pathway.

Anal irrigation systems (generic entry): prescribable in primary care following recommendation and patient training by the continence specialist.

AMBER 3

Mirabegron in combination with solifenacin: in line with updated evidence.

OTHER

Methenamine hippurate (Hiprex®): added as a cost-effective brand to be prescribed in primary care.

Promethazine tablets (Phenergan®): added as a cost-effective brand to be prescribed in primary care.

Trurapi®/ Novorapid®: formulary annotated to highlight Trurapi® as the first-choice insulin aspart product for new patients.

Feature of the month

Inclisiran - learning and upskilling

The NHS Long Term Plan (LTP) identifies cardiovascular disease (CVD) as a clinical priority and the single biggest area where lives can be saved over the next 10 years. It sets out a major ambition to prevent 150,000 strokes, heart attacks and dementia cases. Low density lipoprotein cholesterol (LDL-C) is a proven risk factor for patients with CVD, and the NICE TA for Inclisiran highlights that hypercholesterolemia is undertreated.

[The Inclisiran Information Sheet](#) is a new document and has been produced to assist GPs to prescribe. Protected Learning Time (PLT) sessions have also been planned to support practices.

The East Midlands Academic Health Science Network (EMAHSN) who work in partnership with NHSE as part of the Accelerated Access Collaborative are hosting a free educational event designed to support primary care clinicians in implementing the updated national Lipid Management Pathway.

The webinar is being recorded and the recording will be sent out to those that register. There is no need to dial in for a live session at a particular time.

[Register here to receive the recordings](#)